CSL Limited (ASX:CSL)
258.67
-0.22 (-0.08%)
Feb 21, 2025, 4:10 PM AEST
CSL Limited Revenue
CSL Limited had revenue of $8.48B USD in the half year ending December 31, 2024, with 18.08% growth. This brings the company's revenue in the last twelve months to $15.23B, up 7.41% year-over-year. In the fiscal year ending June 30, 2024, CSL Limited had annual revenue of $14.80B with 11.19% growth.
Revenue (ttm)
$15.23B
Revenue Growth
+7.41%
P/S Ratio
5.08
Revenue / Employee
$465.78K
Employees
32,698
Market Cap
125.25B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
Jun 30, 2020 | 9.15B | 612.20M | 7.17% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Telix Pharmaceuticals | 783.21M |
Ramsay Health Care | 16.66B |
Ansell | 3.00B |
Mesoblast | 8.85M |
Regis Healthcare | 1.01B |
CSL Limited News
- 2 days ago - CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 8 days ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - PRNewsWire
- 8 days ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - Business Wire
- 9 days ago - European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 11 days ago - Half Year 2025 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 11 days ago - CSL Limited 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 11 days ago - CSL Limited (CSLLY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years - Benzinga